

## Calcium sensing by human medullary thyroid carcinoma cells

Peter Ridefelt<sup>a,\*</sup>, Yi-Jia Liu<sup>b</sup>, Jonas Rastad<sup>a</sup>, Göran Åkerström<sup>a</sup>, Erik Gylfe<sup>b</sup>

<sup>a</sup>Department of Surgery, University Hospital, S-751 85 Uppsala, Sweden

<sup>b</sup>Department of Medical Cell Biology, University of Uppsala, Biomedicum, Box 571, S-751 23 Uppsala, Sweden

Received 3 November 1993; revised version received 30 November 1993

### Abstract

Regulation of the cytoplasmic calcium concentration ( $[Ca^{2+}]_i$ ) was studied in fura-2-loaded C-cells from two human medullary thyroid carcinomas (MTC).  $K^+$  depolarization induced sustained rise of  $[Ca^{2+}]_i$ , reversed by verapamil. Elevation of external  $Ca^{2+}$  from 0.5 to 3.0 mM triggered regular oscillations or steady-state increases of  $[Ca^{2+}]_i$ . In  $Ca^{2+}$ -deficient medium  $Sr^{2+}$  caused steady-state increase or oscillations of the 340/380 nm fluorescence ratio. The  $Ca^{2+}$  and  $Sr^{2+}$  actions were partially reversible by verapamil.  $La^{3+}$  and  $Ce^{3+}$  elicited transient  $[Ca^{2+}]_i$  peaks independent of external  $Ca^{2+}$ , but no oscillations. The results indicate that human MTC cells express a parathyroid-like  $Ca^{2+}$  sensor coupled to intracellular mobilization and influx of  $Ca^{2+}$ . A voltage-dependent  $Ca^{2+}$  influx may be of importance for the oscillations of  $[Ca^{2+}]_i$ .

**Key words:** Calcium; Calcitonin; Thyroid neoplasm; Signal transduction

### 1. Introduction

Extracellular  $Ca^{2+}$  regulates the secretion of calcitonin (CT) from C-cells of the thyroid gland. Elevation of external  $Ca^{2+}$  raises  $[Ca^{2+}]_i$  and stimulates CT release [1,2]. However, the mechanisms by which the C-cells sense the extracellular  $Ca^{2+}$  concentration and the transduction of this signal are unknown. Using cell lines derived from rat medullary thyroid carcinoma it was recently shown that the  $Ca^{2+}$  induced increase of  $[Ca^{2+}]_i$  involve oscillations [3,4]. Such oscillations are known to play an important role in the regulation of secretion from a number of different cell types [5]. The present study utilizes microfluorometry and image analysis to investigate cation induced  $[Ca^{2+}]_i$  responses of single human medullary thyroid carcinoma cells loaded with fura-2.

### 2. Materials and methods

#### 2.1. Chemicals

Reagents of analytical grade and deionized water were used. Sigma (St Louis, MO, USA) provided collagenase, DNase and BSA. Fura-2 acetoxymethylester (fura-2/AM) was from Calbiochem (La Jolla, CA, USA) and Ham's F-10, RPMI 1640, FBS, streptomycin, penicillin and L-glutamine from Flow (Irvine, UK), while Pharmacia Biotech (Uppsala, Sweden) provided Percoll.

\*Corresponding author. Fax: (46) (18) 553 601.

**Abbreviations:** CT, calcitonin;  $[Ca^{2+}]_i$ , cytoplasmic calcium concentration; MTC, medullary thyroid carcinoma; BSA, bovine serum albumin; FBS, foetal bovine serum.

#### 2.2. Cell preparation

C-cells were obtained from primary MTC tumors during surgery on two patients with excessively elevated serum calcitonin levels. The specimens were minced with scissors in HEPES-buffered Ham's F-10 with 1.25 mM  $Ca^{2+}$ . A cell suspension was prepared by enzymatic digestion for 60 min at 37°C in the F-10 medium containing 1 mg/ml collagenase, 0.05 mg/ml DNase, 1.25 mM  $Ca^{2+}$  and 1.5% BSA [6]. The cell suspension was filtered through a nylon mesh (125  $\mu$ m) and exposed briefly to a  $Ca^{2+}$ -deficient medium containing 1 mM EGTA. Removal of dead cells and debris was achieved by centrifugation through a 25% standard isotonic Percoll gradient. Cell viability as determined by Trypan blue exclusion exceeded 95%. Cells were cultured for 24–48 h on 22 mm circular microscopic cover glasses in RPMI 1640 medium with 1.25 mM  $Ca^{2+}$  and supplemented with 10% FBS, 50  $\mu$ g/ml streptomycin, 50 IU/ml penicillin, 290  $\mu$ g/ml L-glutamine.

#### 2.3. Measurements of $[Ca^{2+}]_i$

Cells attached to the coverglasses were loaded for 30 min at 37°C with 1.0  $\mu$ M fura-2/AM and rinsed. Loading and fluorescence measurements were performed in buffer containing 25 mM HEPES (pH 7.4), 3 mM glucose, 0.1% BSA, 125 mM  $Na^+$ , 5.9 mM  $K^+$ , 0.5 mM  $Mg^{2+}$  and 0.5 mM  $Ca^{2+}$  and with  $Cl^-$  as the sole anion. Additions of  $Sr^{2+}$ ,  $K^+$ ,  $La^{3+}$  and  $Ce^{3+}$  to the perfusion medium were done as chloride salts. The cover glasses were used as the bottom of an open chamber designed for microscopic work. The chamber wall was a broad silicon rubber ring, 9 mm inner diameter, pressed to the cover glass by the threaded chamber mount and a thin stainless steel ring. Cannulas fixed to this ring were connected to a two-channel peristaltic pump, allowing perfusion of a 2.5 mm medium layer at a rate of 1.0 ml/min. The chamber was placed on the stage of an inverted microscope within a climate box maintained at 37°C by an air-stream incubator. The microscope was equipped for epifluorescence microfluorometry with a 100 $\times$  UV-fluorite objective (Nikon). A 75 W xenon arc lamp combined with 10–13 nm half band-width (HBW) interference filters in an air-turbine time-sharing multichannel spectrofluorometer provided 1 ms excitation light flashes at 340 and 380 nm every 10 ms. Emission was measured with a photomultiplier at 510 nm using a 30 nm HBW filter [7]. In addition a Magiscan system (Applied Imaging, Gateshead, UK) equipped with a filter changer providing a 340/380 nm image pair every 4.5 s was used for image analysis of  $[Ca^{2+}]_i$  [8]. Images were collected through a 30 nm HBW filter at 510 nm with an intensified CCD camera (Extended ISIS-M; Photonic Science, Robertsbridge, UK). The 340/380 nm ratio

frames were calculated after subtraction of background frames using the Tardis program (Applied Imaging). The 340/380 nm fluorescence excitation ratios was used to calculate  $[Ca^{2+}]_i$  using a  $K_d$  of 224, as previously described [9]. Results are presented as mean  $\pm$  S.E.

### 3. Results

In presence of 0.5 mM  $Ca^{2+}$  basal  $[Ca^{2+}]_i$  of the MTC cells was stable at  $56 \pm 3.4$  nM ( $n = 39$ ). When elevating  $Ca^{2+}$  from 0.5 to 3.0 mM the cells responded with rhythmic oscillations of  $[Ca^{2+}]_i$  (Figs. 1–3). The oscillations, which had amplitudes of  $122 \pm 9.4$  nM ( $n = 27$ ), were evident in 9 out of 12 and 18 out of 27 examined cells from the two patients. Generally, the first peak was most prominent, and the ensuing oscillations regular, but some cells displayed more complex and irregular patterns. The non-oscillating cells either exhibited a single  $[Ca^{2+}]_i$  peak or a stable steady-state increase. Oscillatory frequencies were notably different between the two patients, and averaged  $1.97 \pm 0.21$  and  $0.31 \pm 0.024$  per minute, respectively. Addition of 0.1 mM verapamil in presence of 3.0 mM external  $Ca^{2+}$  abolished or markedly reduced the amplitude of the oscillations (Fig. 1), and they were eliminated by lowering of external  $Ca^{2+}$  to 0.5 mM (Figs. 2 and 3).

Introduction of 5–20 mM  $Sr^{2+}$  in a  $Ca^{2+}$ -deficient medium elicited a transient increase followed by oscillations or steady-state elevations of the 340/380 nm fluorescence ratio (Fig. 2). Also the  $Sr^{2+}$ -induced increase in fluorescence ratio exhibited sensitivity to verapamil.

Depolarization with 30 mM  $K^+$  caused sustained in-

crease in  $[Ca^{2+}]_i$ , but no oscillations, and this effect was reversed by verapamil (Fig. 3A). When MTC cells were challenged with 0.2 mM  $La^{3+}$  in presence of 0.5 mM  $Ca^{2+}$ , or with 0.2 mM  $Ce^{3+}$  in a  $Ca^{2+}$ -deficient medium, there were rapid  $[Ca^{2+}]_i$  transients followed by return to basal levels (Fig. 3B,C). Combination of  $La^{3+}$  with 3 mM  $Ca^{2+}$  resulted in a sustained rise of  $[Ca^{2+}]_i$ , which was partially reversed by verapamil (Fig. 3B).

### 4. Discussion

C-cells respond to small elevations of external  $Ca^{2+}$  with rise of  $[Ca^{2+}]_i$  and release of the  $Ca^{2+}$  lowering hormone CT [1]. Due to difficulties in obtaining sufficient amounts of tissue, little is known about regulation of  $[Ca^{2+}]_i$  and CT release in human C-cells. The human MTC cell line TT does not exhibit any changes in either  $[Ca^{2+}]_i$  or secretion in response to elevation of external  $Ca^{2+}$  [10]. Signal transduction may be defective in these cells, since treatment with the ionophore ionomycin raised  $[Ca^{2+}]_i$  and stimulated CT release, and since electroporation made the secretion sensitive to external  $Ca^{2+}$ .

It is apparent from the present study that the C-cells isolated from the two patients with MTC have voltage-dependent  $Ca^{2+}$  channels. Depolarization with  $K^+$  raised  $[Ca^{2+}]_i$ , and this effect was counteracted by verapamil. These findings harmonize with observations on the rat MTC 44–2 and 6–23 cell lines [1,11]. Moreover, agonists and antagonists of voltage-dependent  $Ca^{2+}$  channels




Fig. 1. Digital image analysis of  $[Ca^{2+}]_i$  responses of three fura-2 loaded human MTC cells within the same image field. The cells were challenged with the indicated mM concentrations of  $Ca^{2+}$  and verapamil. The initial concentration of  $Ca^{2+}$  in the perfusion medium was 0.5 mM.




Fig. 2. Effects of  $\text{Sr}^{2+}$  and verapamil on the 340/380 nm fluorescence excitation ratio of fura-2 loaded human MTC cells. Unless otherwise indicated the  $\text{Ca}^{2+}$  concentration of the perfusion medium was 0.5 mM. The cells were challenged with the indicated mM concentrations of  $\text{Ca}^{2+}$ ,  $\text{Sr}^{2+}$  and verapamil.




Fig. 3. Effects of  $\text{K}^+$ ,  $\text{La}^{3+}$  and  $\text{Ce}^{3+}$  on  $[\text{Ca}^{2+}]_i$  of fura-2 loaded MTC cells monitored by fluorescence ratio microfluorimetry. Unless otherwise indicated the  $\text{Ca}^{2+}$  and  $\text{K}^+$  concentration of the perfusion medium were 0.5 and 5.9 mM, respectively. The cells were challenged with the indicated mM concentrations of  $\text{K}^+$ ,  $\text{Ca}^{2+}$ ,  $\text{La}^{3+}$ ,  $\text{Ce}^{3+}$  and verapamil.

stimulate and reduce CT secretion, respectively, from rat thyroparathyroid glands [12] and MTC 6–23 cells [2,13]. Elevation of external  $\text{Ca}^{2+}$  was now found to induce a  $[\text{Ca}^{2+}]_i$  response sensitive to verapamil also in freshly prepared human MTC cells. However, verapamil failed to completely extinguish this response, and it could be speculated also that non-voltage-dependent mechanisms participate in regulation of  $[\text{Ca}^{2+}]_i$  by external  $\text{Ca}^{2+}$ .

Like the C-cells the parathyroid parenchyma secretes a  $\text{Ca}^{2+}$  regulating hormone upon alterations in the extracellular  $\text{Ca}^{2+}$  concentration. The present data provide strong evidence indicating that a parathyroid-like  $\text{Ca}^{2+}$  sensor is present also on human MTC cells. As in the parathyroid a  $[\text{Ca}^{2+}]_i$  response could be elicited by lanthanides [11], and  $\text{La}^{3+}$  has been shown to be restricted to the extracellular space [14].  $\text{La}^{3+}$  and  $\text{Ce}^{3+}$  thus had similar effects, although the former increase and the latter quenches fluorescence of the  $\text{Ca}^{2+}$  indicator fura-2 [15]. Moreover, the earliest detectable effects of the lanthanides in parathyroid [11] and C-cells was mobilization of intracellular  $\text{Ca}^{2+}$  independent of the presence of  $\text{Ca}^{2+}$  in the external medium. Another similarity with the parathyroid is the observation that divalent cations other than  $\text{Ca}^{2+}$  can activate their own influx [16]. This mechanism explains how  $\text{Sr}^{2+}$ , which reacts with fura-2 in a  $\text{Ca}^{2+}$ -like manner [17,18], induced oscillatory and sustained increases in the 340/380 nm fluorescence ratio in the absence of external  $\text{Ca}^{2+}$ , whereas  $\text{La}^{3+}$  and  $\text{Ce}^{3+}$  only triggered a monophasic release of intracellular  $\text{Ca}^{2+}$  under similar conditions.

Although the parathyroid cells lack voltage-dependent  $\text{Ca}^{2+}$  channels [19],  $\text{Ca}^{2+}$  sensing involves cellular depolarization [20,21]. It has been proposed that the depolarization actually is carried by an inward  $\text{Ca}^{2+}$  current [22]. In view of the partial resistance of the  $\text{Ca}^{2+}$  and  $\text{Sr}^{2+}$  responses to verapamil, it seems likely that there is a similar non-voltage-dependent entry of divalent cations in the human MTC cells. Regulation of  $[\text{Ca}^{2+}]_i$  and secretion in C-cells may consequently involve intracellular release of  $\text{Ca}^{2+}$ , and a depolarizing  $\text{Ca}^{2+}$  current through non-voltage-dependent channels participating in the activation of voltage-dependent  $\text{Ca}^{2+}$  entry.

The similarity in  $\text{Ca}^{2+}$  sensing between parathyroid and C-cells makes it tempting to speculate that the presence of voltage-dependent  $\text{Ca}^{2+}$  channels only in the C-cells is a determinant for their oscillatory regulation of  $[\text{Ca}^{2+}]_i$ . Elevation of external  $\text{Ca}^{2+}$  has been found to induce  $[\text{Ca}^{2+}]_i$  oscillations also in the rat C-cell lines MTC 6–23 and 44–2 [3,4], but the former cells required pre-treatment with glucagon or 8-bromo-cAMP to uncover the oscillations. Unlike the MTC 44–2 cells [4], the cells from the present two patients exhibited  $[\text{Ca}^{2+}]_i$  oscillations only during exposure to elevated external  $\text{Ca}^{2+}$ . It could be speculated that the spontaneous oscillatory activity in the MTC 44–2 cells also in low external  $\text{Ca}^{2+}$  might represent functional dedifferentiation, since the

secretion of  $\text{Ca}^{2+}$ -lowering CT should be turned off in a hypocalcemic environment.

Pulsatile release of hormones is considered important for preventing down-regulation of peripheral receptors [23]. Also  $\text{Ca}^{2+}$  homeostasis has been proposed to be regulated by rhythmic variations in parathyroid hormone, CT and vitamin D [24]. Fasting rats display a circadian pattern of CT secretion with two peaks per 24 h [25], but knowledge is lacking about the periodicity of CT secretion during time ranges of hours or shorter. Pulsatile secretion of PTH during short periods is well documented in human subjects with frequency components ranging from 1–6 oscillations/h [26,27]. However, it is unclear at which level this pulsatility is regulated, since isolated parathyroid cells exhibit no apparent oscillations in either  $[\text{Ca}^{2+}]_i$  or secretion [4,28]. In view of the presently observed  $[\text{Ca}^{2+}]_i$  oscillations during steady rise of external  $\text{Ca}^{2+}$ , it is easy to envisage a pacemaker function of the human C-cells in a rhythmically regulated  $\text{Ca}^{2+}$  homeostasis.

The oscillatory frequency was similar in different cells from each of the present patients, but varied considerably between the two tumors. The frequencies are in the same order as the <1 to 12 oscillations per minute observed in the rat MTC 44–2 and 62–3 cell lines [3,4]. If the frequencies are similar for pulsatile release of different  $\text{Ca}^{2+}$  regulating hormones, those presently observed are higher than expected from the available data on pulsatile release of PTH. Such a discrepancy may be due to dedifferentiation or to loss of coordination upon removing the cells from their natural environment.

**Acknowledgements.** The skilful technical assistance of Carina Nordlund and Birgitta Bondeson is gratefully acknowledged. This study was supported by the Swedish Medical Research Council and the Swedish Cancer Society.

## References

- [1] Fried, R.M. and Tashjian, A.H.J. (1986) *J. Biol. Chem.* 261, 7669–7674.
- [2] Muff, R., Nemeth, E.F., Haller-Brem, S. and Fischer, J.A. (1988) *Arch. Biochem. Biophys.* 265, 128–135.
- [3] Eckert, R.W., Scherübl, H., Petzelt, C., Raue, F. and Ziegler, R. (1989) *Mol. Cell. Endocrinol.* 64, 267–270.
- [4] Fajtova, V.T., Quinn, S.J. and Brown, E.M. (1991) *Am. J. Physiol.* 261, E151–E158.
- [5] Berridge, M. (1993) *Nature* 361, 315–325.
- [6] Ridefelt, P., Hellman, P., Wallfelt, C., Åkerström, G., Rastad, J. and Gylfe, E. (1992) *Mol. Cell. Endocrinol.* 83, 211–218.
- [7] Grapengiesser, E., Gylfe, E. and Hellman, B. (1989) *Arch. Biochem. Biophys.* 268, 404–407.
- [8] Gylfe, E., Grapengiesser, E. and Hellman, B. (1991) *Cell Calcium* 12, 229–240.
- [9] Grynkiewicz, G., Poenie, M. and Tsien, R.Y. (1985) *J. Biol. Chem.* 260, 3440–3450.
- [10] Haller-Brem, S., Muff, R., Petermann, J.B., Born, W., Roos, B.A. and Fischer, J.A. (1987) *Endocrinology* 121, 1272–1277.
- [11] Nemeth, E.F. (1990) *Cell Calcium* 11, 323–327.

- [12] Cooper, C.W., Borosky, S.A., Farrell, P.E. and Steinsland, O.S. (1986) *Endocrinology* 118, 545–549.
- [13] Scherübl, H., Kleppisch, T., Zink, A., Raue, F., Krautwurst, D. and Hescheler, J. (1993) *Am. J. Physiol.* 264, E354–E360.
- [14] Gylfe, E., Johansson, H., Larsson, R., Nygren, P., Rastad, J., Wallfelt, C. and Åkerström, G. (1987) in: *Calcium Regulation and Bone Metabolism: Basic and Clinical Aspects*, Vol. 9, pp. 33–38, (Cohn, D.V., Martin, T.J. and Meunier, P.J., Eds.) Elsevier, Amsterdam.
- [15] Gylfe, E. (1988) *J. Biol. Chem.* 263, 5044–5048.
- [16] Johansson, H., Larsson, R., Wallfelt, C., Rastad, J., Åkerström, G. and Gylfe, E. (1988) *Mol. Cell. Endocrinol.* 59, 77–82.
- [17] Schilling, W.P., Rajan, L. and Strobl-Jager, E. (1989) *J. Biol. Chem.* 264, 12838–12848.
- [18] Kwan, C.-Y. and Putney Jr, J.W. (1990) *J. Biol. Chem.* 265, 678–684.
- [19] Wallfelt, C., Larsson, R., Johansson, H., Rastad, J., Åkerström, G., Ljunghall, S. and Gylfe, E. (1985) *Acta Physiol. Scand.* 124, 239–245.
- [20] Bruce, B.R. and Anderson, N.C. (1979) *Am. J. Physiol.* 236, C15–C21.
- [21] López-Barneo, J. and Armstrong, C.M. (1983) *J. Gen. Physiol.* 82, 269–294.
- [22] Wallfelt, C., Lindh, E., Larsson, R., Johansson, H., Rastad, J., Åkerström, G. and Gylfe, E. (1988) *Biochim. Biophys. Acta* 969, 257–262.
- [23] Lefebvre, P.J., Paolisso, G., Scheen, A.J. and Henquin, J.C. (1987) *Diabetologia* 30, 443–452.
- [24] Staub, J.F., Tracqui, P., Lausson, S., Milhaud, G. and Perault-Staub, A.M. (1989) *Bone* 10, 77–86.
- [25] Lausson, S., Staub, J.F., Milhaud, G. and Perault-Staub, A.M. (1985) *J. Endocrinol.* 107, 389–395.
- [26] Harms, H.-M., Kaptaina, U., Külpmann, W.-R., Brabant, G. and Hesch, R.-D. (1989) *J. Clin. Endocrinol. Metab.* 69, 843–851.
- [27] Samuels, M.H., Veldhuis, J., Cawley, C., Urban, R.J., Luther, M., Bauer, R. and Mundy, G. (1993) *J. Clin. Endocrinol. Metab.* 77, 399–403.
- [28] Dempster, D.W., Tobler, P.H., Olles, P., Born, W. and Fischer, J.A. (1982) *Endocrinology* 111, 191–195.